In a prospective, multicenter study, the 31-GEP identified patients at increased risk of tumor recurrence and added significant prognostic value to AJCC staging. J of Skin [Internet]. 2024 Nov. 18 [cited 2025 May 18];8(6):s504. Available from: https://skin.dermsquared.com/skin/article/view/3058